Key statistics
On Friday, Fibrobiologics Inc (SG0:FRA) closed at 0.172, 0.58% above its 52-week low of 0.171, set on Jan 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.172 |
|---|---|
| High | 0.172 |
| Low | 0.172 |
| Bid | 0.208 |
| Offer | 0.228 |
| Previous close | 0.216 |
| Average volume | 2.74k |
|---|---|
| Shares outstanding | 66.52m |
| Free float | 54.64m |
| P/E (TTM) | -- |
| Market cap | 15.11m USD |
| EPS (TTM) | -0.4809 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
Announcements
- FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
- FibroBiologics to Present at the DealFlow Discovery Conference
- FibroBiologics CEO Issues Letter to Shareholders
- FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
- FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
- FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
- FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
- FibroBiologics Announces Payoff of Outstanding Debt
More ▼
